Startpagina>Klinisch wetenschappelijk onderzoek>Klinische studies>ILLUMINATE

How to use the speech recognition tool?

NCT03913143

ILLUMINATE

A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).

Type: Interventional



Status of the trial: Active, Not recruiting

Orphan Drug Recognition: No

Inclusion

  • Opening Date: 2019-04-04
  • Closing Date: 2021-12-04

Criteria

More information

Children: Yes

Adults: Yes

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: